Fig. 3From: Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study(A) Progression-free survival and (B) overall survival since the beginning of first-line chemotherapyBack to article page